Currently, there are 100.80M common shares owned by the public and among those 99.26M shares have been available to trade.
The company’s stock has a 5-day price change of 4.05% and -2.70% over the past three months. EHC shares are trading 2.59% year to date (YTD), with the 12-month market performance up to 35.75% higher. It has a 12-month low price of $69.72 and touched a high of $104.55 over the same period. EHC has an average intraday trading volume of 659.61K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.78%, -3.29%, and 4.26% respectively.
Institutional ownership of Encompass Health Corp (NYSE: EHC) shares accounts for 96.31% of the company’s 100.80M shares outstanding.
It has a market capitalization of $9.55B and a beta (3y monthly) value of 0.91. The stock’s trailing 12-month PE ratio is 22.87, while the earnings-per-share (ttm) stands at $4.14. The company has a PEG of 1.30 and a Quick Ratio of 1.04 with the debt-to-equity ratio at 1.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.65% over the week and 1.89% over the month.
Analysts forecast that Encompass Health Corp (EHC) will achieve an EPS of 1.02 for the current quarter, 1.2 for the next quarter and 4.77 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.96 while analysts give the company a high EPS estimate of 0.96. Comparatively, EPS for the current quarter was 0.95 a year ago. Earnings per share for the fiscal year are expected to increase by 18.08%, and 11.05% over the next financial year. EPS should grow at an annualized rate of 17.63% over the next five years, compared to 3.48% over the past 5-year period.
Looking at the support for the EHC, a number of firms have released research notes about the stock. KeyBanc Capital Markets stated their Overweight rating for the stock in a research note on October 11, 2024, with the firm’s price target at $115. Leerink Partners coverage for the Encompass Health Corp (EHC) stock in a research note released on July 10, 2024 offered a Outperform rating with a price target of $100. Barclays was of a view on March 06, 2024 that the stock is Overweight, while Barclays gave the stock Equal Weight rating on March 14, 2023, issuing a price target of $57. UBS on their part issued Buy rating on September 24, 2021.
